Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03985527 · ClinicalTrials.gov registry record · NA
Janus Feasibility Study
A NA study of Sleep Apnea Syndromes, sponsored by Respicardia.
- Completed
- Registry status
- NA
- Development phase
- 29
- Enrollment target
- 3
- Study locations
NCT03985527: Completed NA study of Sleep Apnea Syndromes, sponsored by Respicardia.
NCT03985527 is a NA study of Sleep Apnea Syndromes that has completed, run by Respicardia. The registered enrollment target is 29 participants, below the 322-participant average among 8 other Sleep Apnea Syndromes trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03985527, a NA study of Sleep Apnea Syndromes, has completed, sponsored by Respicardia.
- COMPLETED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this feasibility study is to assess whether an alternative transvenous lead location affects respiration and airway physiology during a commercial remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator) implant procedure.
Primary Outcome
The primary objective is to assess acute changes in respiration and airway physiology during the respiration cycle during a commercial remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator) implant.
Conditions Studied
Interventions
- DEVICE Transvenous nerve stimulation
Study Locations (3)
North Carolina
- Novant Health Forsyth Medical Center - Winston-Salem
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Pennsylvania
- Bryn Mawr Medical Specialists Association - Bryn Mawr
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2020-01-09 |
| Est. Completion | 2025-12-12 |
| Phase | NA |
What the finished NCT03985527 record still lists
NCT03985527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 322-participant average among 8 other Sleep Apnea Syndromes trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Sleep Apnea Syndromes appearing as the primary indexed condition, and to 1 intervention - of which Transvenous nerve stimulation is the first listed.
NCT03985527 reports a single indexed study location in North Carolina, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03985527 about?
NCT03985527 is a clinical study titled "Janus Feasibility Study". The purpose of this feasibility study is to assess whether an alternative transvenous lead location affects respiration and airway physiology during a commercial remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator) implant procedure.
What is the current status of trial NCT03985527?
This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2020-01-09. Estimated completion is 2025-12-12.
What conditions does trial NCT03985527 study?
This clinical trial studies the following conditions: Sleep Apnea Syndromes.
What interventions are being tested in trial NCT03985527?
The interventions under investigation include: Transvenous nerve stimulation (DEVICE).
Who is sponsoring clinical trial NCT03985527?
This trial is sponsored by Respicardia, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03985527 being conducted?
This trial has 3 study locations across North Carolina, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sleep Apnea Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03985527's enrollment target sits among peer trials
29 8th of 8 higher than 1 of 8 other Sleep Apnea Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sleep Apnea Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Home Apnea Testing in CHildren Trial
RECRUITING · NA
-
Evaluation of Hypoglossal Nerve Stimulation in Humans With Obstructive Sleep Apnea
COMPLETED · NA
-
WatchPAT Device Validation Study Compared to Polysomnography
COMPLETED · NA
-
Prevalence of Sleep-Disordered Breathing in Children
COMPLETED
-
Apnea Positive Pressure Long-Term Efficacy Study
COMPLETED · Phase 3
-
Evaluation of the Reliability and Validity of a Diagnostic Sleep Disorders Questionnaire
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI